Back to top
more

QIAGEN (QGEN)

(Delayed Data from NYSE)

$45.69 USD

45.69
1,274,235

-0.30 (-0.65%)

Updated May 17, 2024 04:00 PM ET

After-Market: $45.69 0.00 (0.00%) 7:04 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Allogene Therapeutics (ALLO) Soars 8.4%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Allogene Therapeutics (ALLO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Illumina (ILMN) Debuts TSO Comprehensive Test in Europe

by Zacks Equity Research

Illumina's (ILMN) novel CE-marked IVD kit for comprehensive genomic profiling will enable clinicians to match cancer patients with available therapies.

Illumina (ILMN) Invests in Seven Additional Genomics Startups

by Zacks Equity Research

Illumina's (ILMN) investment in seven new genomics companies is intended to advance breakthrough therapeutics, diagnostics, DNA storage, mental wellness and sustainable foods applications.

Why Is Qiagen (QGEN) Down 11.3% Since Last Earnings Report?

by Zacks Equity Research

Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Is QIAGEN (QGEN) a Great Stock for Value Investors?

by Zacks Equity Research

Is QIAGEN (QGEN) a great pick from the value investor's perspective right now? Read on to know more.

QIAGEN (QGEN) Q4 Earnings Surpass Estimates, Margins Down

by Zacks Equity Research

High demand for COVID-19 test products and improving trends in the non-COVID portfolio drove QIAGEN's (QGEN) fourth-quarter revenues.

Here's Why You Should Retain QIAGEN (QGEN) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about QIAGEN's (QGEN) progress with testing solutions and strategic collaborations.

QIAGEN (QGEN) to Boost Testing Capacity With Liquid-Based Kit

by Zacks Equity Research

QIAGEN's (QGEN) artus SARS-CoV-2 Prep&Amp UM is faster than standard processes and can spot the virus more reliably, including the new Omicron variant.

The Zacks Analyst Blog Highlights: Thermo Fisher Scientific Inc., QIAGEN N.V. Quest Diagnostics and Quidel Corp.

by Zacks Equity Research

Thermo Fisher Scientific Inc., QIAGEN N.V. Quest Diagnostics,and Quidel Corp. are highlighted in this analyst blog.

Riya Anand headshot

3 Diagnostics Stocks in Focus Amid the Omicron Outbreak

by Riya Anand

Stocks like Thermo Fisher (TMO), QIAGEN (QGEN) and Quidel (QDEL) are expected to gain from increasing testing demand.

QIAGEN (QGEN), Denovo to Develop CDx Test for Lymphoid Cancer

by Zacks Equity Research

QIAGEN (QGEN) will develop a diagnostic assay that can identify the Denovo Genomic Marker 1 in patients with lymphoid cancer.

Here's Why You Should Retain QIAGEN (QGEN) Stock for Now

by Zacks Equity Research

Investors are optimistic about QIAGEN (QGEN) on strong third-quarter results and raised 2021 guidance.

QIAGEN (QGEN) Gets CE Mark for QuantiFERON SARS-CoV-2 Assay

by Zacks Equity Research

QIAGEN's (QGEN) QuantiFERON SARS-CoV-2 assay enables a comprehensive assessment of immunity developed by COVID-19 vaccines.

Qiagen (QGEN) Down 1.9% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

QIAGEN (QGEN), DiaSorin to Broaden Access to Latent TB Testing

by Zacks Equity Research

QIAGEN (QGEN) and DiaSorin gained FDA approval for their jointly-created LIAISON QuantiFERON-TB Gold Plus assay for use on DiaSorin's automated LIAISON XS platform.

QIAGEN (QGEN) Q3 Earnings Surpass Estimates, 2021 View Up

by Zacks Equity Research

QIAGEN (QGEN) exited third-quarter 2021 with better-than-expected results on strength in the two major customer classes driving the top line.

Qiagen (QGEN) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

Qiagen (QGEN) delivered earnings and revenue surprises of 9.43% and 9.73%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Will Qiagen (QGEN) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Qiagen (QGEN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Qiagen (QGEN) is a Top Growth Stock for the Long-Term

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

QIAGEN's (QGEN) New Manchester Facility to Fortify UK Foothold

by Zacks Equity Research

QIAGEN's (QGEN) new campus is expected to bring the benefits of transformational molecular diagnostics to Manchester and the global healthcare market.

QIAGEN (QGEN) New Launch to Aid Global TB Elimination Targets

by Zacks Equity Research

QIAGEN's (QGEN) QIAreach QuantiFERON-TB test is now accessible in high burden, low-resource regions.

Qiagen (QGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

by Zacks Equity Research

Qiagen (QGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 Reasons Growth Investors Will Love Qiagen (QGEN)

by Zacks Equity Research

Qiagen (QGEN) could produce exceptional returns because of its solid growth attributes.

QIAGEN (QGEN) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

New product approvals, partnerships in the diagnostic solutions category and sustained success in other product areas are likely to have contributed to QIAGEN's (QGEN) growth.

PerkinElmer's (PKI) Arm Gets FDA EUA Nod for Latest Assay

by Zacks Equity Research

PerkinElmer's (PKI) unit receives FDA's EUA nod for its Anti-SARS-CoV-2 S1 Curve ELISA (IgG) that could aid in future understanding and provide insights on immune responses to SARS-CoV-2.